Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Karen S. Ho"'
Autor:
Jimin Ren, Richard B. Dewey, Austin Rynders, Jacob Evan, Jeremy Evan, Shelia Ligozio, Karen S. Ho, Peter V. Sguigna, Robert Glanzman, Michael T. Hotchkin, Benjamin M. Greenberg
Publikováno v:
Journal of Nanobiotechnology, Vol 21, Iss 1, Pp 1-11 (2023)
Abstract Background Impaired brain energy metabolism has been observed in many neurodegenerative diseases, including Parkinson’s disease (PD) and multiple sclerosis (MS). In both diseases, mitochondrial dysfunction and energetic impairment can lead
Externí odkaz:
https://doaj.org/article/26003f0f906d41cca6145faaa4fda104
Autor:
Steve Vucic, Parvathi Menon, William Huynh, Colin Mahoney, Karen S. Ho, Alan Hartford, Austin Rynders, Jacob Evan, Jeremy Evan, Shelia Ligozio, Robert Glanzman, Michael T. Hotchkin, Matthew C. Kiernan
Publikováno v:
EClinicalMedicine, Vol 60, Iss , Pp 102036- (2023)
Summary: Background: CNM-Au8® is a catalytically-active gold nanocrystal neuroprotective agent that enhances intracellular energy metabolism and reduces oxidative stress. The phase 2, randomised, double-blind, placebo-controlled trial and open label
Externí odkaz:
https://doaj.org/article/33e21743691143f19aa48dd9c22dd05c
Autor:
Jimin Ren, Richard B. Dewey, Austin Rynders, Jacob Evan, Jeremy Evan, Shelia Ligozio, Karen S. Ho, Peter V. Sguigna, Robert Glanzman, Michael T. Hotchkin, Benjamin M. Greenberg
Publikováno v:
Journal of Nanobiotechnology, Vol 22, Iss 1, Pp 1-1 (2024)
Externí odkaz:
https://doaj.org/article/57fe061ce12f492080906a7190fb3270
Autor:
Matthew C Kiernan, William Huynh, Steve Vucic, Parvathi Menon, Austin Rynders, Karen S Ho, Robert Glanzman, Michael T Hotchkin
Publikováno v:
BMJ Open, Vol 11, Iss 1 (2021)
Introduction Amyotrophic lateral sclerosis (ALS) is an adult-onset, progressive and universally fatal neurodegenerative disorder. In Europe, Australia and Canada, riluzole is the only approved therapeutic agent for the treatment of ALS, while in the
Externí odkaz:
https://doaj.org/article/5b34b89dba1c4672a117a2d5413de1b6
Autor:
Zixin Wang, Alexandre Henriques, Laura Rouvière, Noëlle Callizot, Lin Tan, Michael T. Hotchkin, Rodrigue Rossignol, Mark G. Mortenson, Karen S. Ho, Hui Wang
Bioenergetic deficits, such as mitochondrial impairments and dysfunction in glucose metabolism, have been identified as significant contributors to neurodegenerative diseases. Nevertheless, identifying safe and effective means to address intracellula
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::44c65e7412c38818596575d98ee17902
https://doi.org/10.1101/2023.05.08.539856
https://doi.org/10.1101/2023.05.08.539856
Autor:
Garrett Bullock, Jared A. Jaffey, Leah A. Cohn, Erika Sox, Eric T. Hostnik, Kyle D. Hutcheson, Erin Matero, Karen S. Hoffmann, Gary S. Johnson, Martin L. Katz
Publikováno v:
Journal of Veterinary Internal Medicine, Vol 38, Iss 5, Pp 2431-2443 (2024)
Abstract Background Human patients with Ehlers‐Danlos syndrome (EDS) are categorized into subtypes based on causative genetic variants and phenotypes. The classical form of EDS, primarily caused by variants in COL5A1 or COL5A2, is a very common sub
Externí odkaz:
https://doaj.org/article/e3f4160d8c9c4938a6ba6147b1ed522a
Autor:
Aparna Prasad, Megan M. Martin, E. Robert Wassman, Rena Vanzo, Sarah T. South, Karen S. Ho, Hope Twede
Publikováno v:
European Journal of Medical Genetics. 62:15-20
Copy number variants (CNV)s involving KANK1 are generally classified as variants of unknown significance. Several clinical case reports suggest that the loss of KANK1 on chromosome 9p24.3 has potential impact on neurodevelopment. These case studies a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26e639a5b950594bb1c0725e00ebe3a1
https://doi.org/10.1016/j.ejmg.2018.04.012
https://doi.org/10.1016/j.ejmg.2018.04.012
Autor:
Karen S. Ho, Leah M. Markham, Hope Twede, Amanda Lortz, Lenora M. Olson, Xiaoming Sheng, Cindy Weng, E. Robert Wassman, Tara Newcomb, John C. Carey, Agatino Battaglia
Publikováno v:
Epilepsy & Behavior. 81:55-61
Seizures are present in over 90% of infants and children with Wolf-Hirschhorn syndrome (WHS). When present, they significantly affect quality of life. The goal of this study was to use caregiver reports to describe the comparative efficacies of commo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8533f49f2f0d7efbfaa064c93a21795
https://doi.org/10.1016/j.yebeh.2017.12.008
https://doi.org/10.1016/j.yebeh.2017.12.008
Autor:
Benjin D. Facer, Michael G. Stewart, Stephen Karlik, Mikhail Merzliakov, Adam R. Dorfman, Karen S. Ho, Andrew P. Robinson, Mark G. Mortenson, Jon D. Facer, Richard Watt, Joanne Zhongyan Zhang, Haley E. Titus, Michael T. Hotchkin, Molly Karl, Robert H. Miller, Stephen D. Miller, Noah D. Christian
Publikováno v:
Scientific Reports
Scientific Reports, Vol 10, Iss 1, Pp 1-16 (2020)
Scientific Reports, Vol 10, Iss 1, Pp 1-16 (2020)
Development of pharmacotherapies that promote remyelination are a high priority for multiple sclerosis (MS) due to their potential for neuroprotection and restoration of function through repair of demyelinated lesions. A novel preparation of clean-su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4a5f4003cf06b8a67ad9bac1f4174a3
Autor:
Michael T Hotchkin, Matthew C. Kiernan, Karen S. Ho, Robert Glanzman, Steve Vucic, Parvathi Menon, Austin Rynders, William Huynh
Publikováno v:
BMJ Open
BMJ Open, Vol 11, Iss 1 (2021)
BMJ Open, Vol 11, Iss 1 (2021)
IntroductionAmyotrophic lateral sclerosis (ALS) is an adult-onset, progressive and universally fatal neurodegenerative disorder. In Europe, Australia and Canada, riluzole is the only approved therapeutic agent for the treatment of ALS, while in the U
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c81b32c25ab66bce3cfaef01a7623e0
https://doi.org/10.1136/bmjopen-2020-041479
https://doi.org/10.1136/bmjopen-2020-041479